Program Offering and Eligibility

Program offering

If you have been prescribed HEMLIBRA and you are eligible, you may be able to get help with your drug costs.

The program helps with $15,000 per year in drug co-pay costs. You pay a $5 co-pay per treatment.

Eligibility

You are eligible if you:
  • Have been prescribed HEMLIBRA for an FDA-approved indication
  • Are 18 years of age or older, or have a legal guardian 18 years of age or older to manage the program
  • Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance marketplaces
  • Do not receive support from the Genentech® Access to Care Foundation (GATCF) or any other independent co-pay assistance foundations for HEMLIBRA
  • Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (eg, Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD or TRICARE)
  • Do not reside in a state where the program is prohibited

 

If you are not eligible for the HEMLIBRA Co-pay Program, there may be other options for co-pay assistance. Call (866) HEMLIBRA (866-436-5427) or visit HEMLIBRA.com/access to learn more.

Indication and Important Safety Information

 

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. HEMLIBRA may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including thrombotic microangiopathy (TMA), and blood clots (thrombotic events). If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

How should I use HEMLIBRA?

  • Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.
  • You may continue prophylactic use of factor VIII for the first week of HEMLIBRA prophylaxis.

What should I know about lab monitoring?

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.

The most common side effects of HEMLIBRA include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain.

These are not all of the possible side effects of HEMLIBRA. Speak to your healthcare provider for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see the HEMLIBRA full Prescribing Information and Medication Guide for more important safety information including Serious Side Effects.